EB2-NIW Approved!
Another powerful success story!
We are thrilled to announce another I-140 approval, this time through Premium Processing after our editorial team answered a Request for Evidence in full. Our client’s research into novel diagnostics and therapeutics for heme-related diseases speaks directly to a national health priority.
| Processing Type | Premium Processing |
| Priority Date | March 22, 2024 |
| RFE Issued | November 13, 2024 |
| RFE Response Filed | February 10, 2025 |
| Premium Processing Upgrade | January 14, 2026 |
| I-140 Approved | July 11, 2026 |
| Field of Expertise | Chemistry, biochemistry, and molecular diagnostics for heme-related diseases |
| Degrees | PhD in Chemistry M.Sc. in Toxicology (United Kingdom) B.Sc. in Biochemistry, First Class |
Why It Matters
- Alzheimer’s disease affects 6.9 million Americans, with cases set to double by 2060
- Alzheimer’s care costs could surpass $1 trillion a year by 2050
- The work aligns with the NIH BRAIN Initiative and the National Alzheimer’s Project Act
Key Achievements
- 4 peer-reviewed publications
- 18 citations on published work
- 10 conference presentations, including an invited discussion leader role
- 10+ awards, honors, and fellowships
- Independent expert recommendation letters
Why This Petition Succeeded
Substantial Merit & National Importance. The endeavor was tied directly to NIH priorities and the national Alzheimer’s agenda, establishing clear public-health value.
Well Positioned to Advance the Endeavor. Peer-reviewed publications, citations, conference leadership, awards, and independent expert letters established him as uniquely qualified.
Labor Certification Waiver Justified. His specialized research serves the field and national health interests, demonstrating impact well beyond any single employer.
The RFE, Answered
When the Request for Evidence arrived, our editorial team addressed all three points USCIS raised. An RFE is not a denial. With the right response, it is a step toward approval.
Proposed Endeavor
Developing novel diagnostics and therapeutics for heme-related diseases, with a focus on Alzheimer’s disease and tuberculosis, advancing early detection and treatment in line with national health priorities.
